Teva Pharmaceutical Industries
Israel's largest pharmaceutical manufacturer and a global leader in generic and specialty pharmaceuticals, with headquarters in Tel Aviv and listings on TASE and Nasdaq.
Teva Pharmaceutical Industries is the world's largest generic pharmaceutical manufacturer by revenue and Israel's flagship pharma company. Founded in 1901 as a small Tel Aviv pharmacy, Teva has grown into a global multinational with operations across 60+ countries and a presence in over 140 markets.
Business Model & Scale
Teva manufactures generic and specialty pharmaceuticals, biosimilars, and active pharmaceutical ingredients (APIs). Annual revenue exceeds $16 billion; it employs approximately 40,000 people globally. The company is listed on both the Tel Aviv Stock Exchange (TASE) and NASDAQ, with significant institutional ownership in the US and Europe.
History & Pivots
Teva's transformation from a regional player to global generics leader occurred through aggressive acquisitions (Copaxone from Elan, Allergan's generics unit, Huntingdon Life Sciences). In the mid-2000s, Copaxone (glatiramer acetate)—a multiple sclerosis drug—accounted for ~25% of revenue but faced patent expiration and generic competition. The firm diversified into broader specialty pharma and biosimilars to offset that decline.
Regulatory & Patent Exposure
Teva operates in highly regulated markets (US FDA, European Medicines Agency, Israeli Ministry of Health). Generic pharma carries thin margins (often single-digit) but high volume. Patent litigation, regulatory delays, and pricing pressure are existential risks. US opioid litigation settlements have imposed significant liabilities.
Israeli Tech Ecosystem Integration
Teva partners with Israeli biotech firms, academic institutions (Hebrew University, Tel Aviv University), and research organizations (Weizmann Institute) on drug discovery and development. These partnerships position Teva as an anchor buyer of Israeli biotech IP and talent.
Market Position & Competitors
Teva competes globally with Sandoz, Mylan (now Viatris), and others in generics; specialty pharma competes with Abbvie, Amgen, and specialized firms. In Israel, Teva is the dominant pharma employer and major tax contributor.